Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Muscle-invasive Bladder Cancer: full-pipeline trial registry
3 of 11 indexed Muscle-invasive Bladder Cancer trials are currently recruiting.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 3 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Muscle-invasive Bladder Cancer: 11 US clinical trials tracked, 3 recruiting.
Muscle-invasive Bladder Cancer is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 3 of these trials.
Enrollment posture brief
Registry condition muscle-invasive-bladder-cancer
OPEN 3 | RECR 27% | LATE 5 | EARLY 4 | RANK #1577 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Atherosclerotic Cardiovascular Disease (27% recruiting · 22 trials)
Muscle-invasive Bladder Cancer lists 3 open slots (27% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Muscle-invasive Bladder Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Muscle-invasive Bladder Cancer is recruiting below its size-band peers.
3 of 11 indexed trials (27.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Muscle-invasive Bladder Cancer research.
AstraZeneca accounts for 3 of 11 trials (27.3%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical Muscle-invasive Bladder Cancer enrolment sits around 117 participants.
Median target enrolment is 117 among the 11 trials that report a genuine target (sentinel values excluded). 4 of those (36.4%) plan for fewer than 100 participants.
-
Muscle-invasive Bladder Cancer research is mostly interventional.
10 interventional and 1 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
Sample Collection for Ongoing Research and Product Evaluation Study
Natera
NCT07318051
mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer
University of California, Irvine
NCT06335667
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence
University of California, Irvine
NCT06682728
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
AstraZeneca
NCT03732677
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
Bristol-Myers Squibb
NCT03661320
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
Hoffmann-La Roche
NCT04660344
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
AstraZeneca
NCT04960709
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
AstraZeneca
NCT02546661
A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer
Bristol-Myers Squibb
NCT04209114
BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy
Masonic Cancer Center, University of Minnesota
NCT03294304
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
Dana-Farber Cancer Institute
NCT00808639
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
| Phase 3 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Muscle-invasive Bladder Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Muscle-invasive Bladder Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Muscle-invasive Bladder Cancer page
11 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Muscle-invasive Bladder Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Muscle-invasive Bladder Cancer trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Muscle-invasive Bladder Cancer condition card totals 11 registered trials; most-linked intervention Gemcitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.